Stable Supply of Pharmaceuticals, Capital Investment and Production Efficiency Improvements

「In the pharmaceuticals CDMO division, within the CMO business, production capacity increased through the introduction of a two-shift system for topical product manufacturing and the restart of allergen manufacturing facilities that had been under renovation during the previous fiscal year.」

「Performance fell below the initial plan because orders for contract manufacturing projects involving high-potency injectable manufacturing facilities were delayed.」

「At 岩城製薬佐倉工場株式会社, production volume declined due to changes in plans for contract manufacturing projects. The company nevertheless continued to focus on the stable supply of contract-manufactured products and on continually improving product quality and operating efficiency through small-group activities and other initiatives.」

「The company refurbished its high-potency injectable manufacturing building and is preparing to establish the necessary operating structure for a start-up this autumn. It is also proceeding with capital investments to expand contract manufacturing capacity for solid formulations.」

「The company is also refurbishing its high-potency injectable manufacturing building and preparing for operations to begin this autumn, while making capital investments to expand contract manufacturing capacity for solid formulations.」

「The affiliated company 岩城製薬佐倉工場株式会社 continued to focus on the stable supply of contract-manufactured products, and existing contract-manufactured products remained firm. The company is also refurbishing its high-potency injection building and preparing for operations to begin this autumn.」

「At 岩城製薬佐倉工場株式会社, delivery of equipment imported from Europe was delayed due to Russia's invasion of Ukraine, delaying completion of the injection facilities by approximately 2 months.」

「In the pharmaceuticals business, amid the spread of COVID-19, we focused on establishing sales DX launched in December last year, stabilizing production of the originator product transferred to us in April this year, developing new generic products, and expanding sales of a new product for aesthetic clinics launched in July, while maintaining a stable supply of safe and reliable pharmaceuticals.」

「Against this backdrop, in the prescription pharmaceuticals field, we worked to maintain stable supply and secure trust under legal compliance, introduced a sales support system in December last year to promote DX, and used it to expand sales of Nizoral Lotion, which we assumed in April this year.」

「In the prescription pharmaceuticals field, with quality as our top priority and under legal compliance and a stable supply system, we pursued adoption of the new alopecia treatment and fully launched sales DX in December, centered on topical products.」

「In the prescription pharmaceuticals field, with quality as our top priority and under legal compliance and a stable supply system, we worked to have our new treatment for alopecia, launched in June, adopted and engaged in appropriate information provision activities for dispensing pharmacies and medical institutions, centered on topical products.」

「At 岩城製薬佐倉工場株式会社, we actively pursued contract manufacturing opportunities and responded to requests for increased production.」

「In the prescription pharmaceuticals field, while visits to medical institutions such as private dermatology practices were limited under measures to address COVID-19, we engaged in appropriate information provision activities for dispensing pharmacies and medical institutions, including the introduction of digital transformation tools, centered on major topical products and treatments for male-pattern hair loss.」

「As of the end of the consolidated fiscal year, the major capital investments in new facilities planned by the Group were as follows: Pharmaceuticals business: 3,691,209 — injection manufacturing lines and related facilities at 岩城製薬佐倉工場株式会社. Fine chemicals business: 545,000 — expansion of highly pharmacologically active API manufacturing capabilities at 岩城製薬株式会社.」

「In the pharmaceuticals business, within the prescription pharmaceuticals field, we engaged in appropriate information provision activities for dispensing pharmacies and medical institutions, centered on major topical products and new products such as a treatment for male-pattern hair loss. Visits to wholesalers and medical institutions were limited, including visits to private dermatology practices, to prevent the spread of COVID-19.」

「During the consolidated fiscal year, we made investments including ¥432 million for the construction of a new analytical center (IW North Cube) to handle a wide variety of raw materials containing highly pharmacologically active substances, and ¥499 million for information systems upgrades.」

「In the pharmaceuticals business, under a stable supply system, we focused on major topical products, including essential medicines, and added new products such as a treatment for male-pattern hair loss. We engaged in appropriate information provision activities at medical institutions, including dispensing pharmacies and DPC hospitals. We also reviewed product profitability to make use of public programs, including repricing for products with inadequate profitability. As a result, sales of our core topical products generally remained strong, with particularly significant growth in sales of major products such as corticosteroids.」

「Against this backdrop, in the prescription pharmaceuticals business, we worked to provide appropriate information at medical institutions, including dispensing pharmacies and DPC hospitals, while maintaining a stable supply system and adding treatments for male-pattern hair loss to our major topical products, including essential medicines. We also reviewed product profitability. As a result, sales of our core topical products generally remained strong, with particularly significant growth in sales of major products such as corticosteroids.」

「In the pharmaceuticals business, prescription drugs were supplied under a stable supply system. We added new products, including a treatment for male-pattern hair loss, centered on our major topical products, and engaged in proactive information provision activities at medical institutions, including dispensing pharmacies and DPC hospitals.」

「We made investments including ¥189 million for the construction of a new analytical center to handle a wide variety of raw materials containing highly pharmacologically active substances.」

「In the pharmaceutical field, under a stable supply system, we actively provided information to medical institutions, including dispensing pharmacies and DPC hospitals, covering key topical products and new products such as treatments for male-pattern hair loss. Amid an increasingly challenging environment due to annual drug price revisions and other factors, we also pursued designation for essential drugs and products subject to repricing for unprofitable products to ensure stable supply and improve profitability in the future.」

「We worked to obtain designation for essential drugs and products subject to repricing for unprofitable products, with the aim of ensuring stable supply and improving profitability in the future. As a result, ethical drugs generally performed well, with sales of key topical products, particularly antifungal agents and corticosteroids, increasing significantly.」

「In the pharmaceutical field, we worked to introduce manufacturing facilities for stable supply and establish an efficient production system. We also actively provided information to medical institutions, including dispensing pharmacies and DPC hospitals, focusing on key topical products and adding new products such as treatments for male-pattern hair loss.」

「In addition to the full-scale operation of production facilities introduced at the beginning of the period to ensure stable supply, we continued improvement activities to enhance productivity. As a result, sales at existing customers remained firm and the number of new customers adopting the products increased, resulting in strong sales of ethical drugs, mainly topical products.」

「We also promoted investment in production facilities for stable supply and various improvement activities to enhance productivity. As a result, sales of ethical drugs grew significantly, led by key topical products including treatments for atopic dermatitis and antifungal agents.」

「To address growing demand for generic drugs, we focused on capital investment for stable supply, production efficiency improvements, and active information provision to medical institutions, including dispensing pharmacies and DPC hospitals, working to expand sales. We also actively audited domestic and overseas raw material manufacturers to improve product reliability.」

「To address growing demand for generic drugs, we promoted supply chain efficiency and established a stable supply system, while actively providing information to medical institutions, including dispensing pharmacies and DPC hospitals, focusing on key topical products.」

「In the pharmaceutical field, amid a challenging environment following the April drug price revision, we actively provided information to medical institutions, including dispensing pharmacies and DPC hospitals, focusing on key topical products. As a result, sales of ethical drugs grew significantly, led by key topical products including treatments for psoriasis vulgaris. Operating profit also increased due to lower SG&A expenses, including upfront development and advertising expenses.」

「In the pharmaceutical field, we promoted capital investment to ensure stable supply and activities to improve production efficiency, while actively providing information to medical institutions, including dispensing pharmacies and DPC hospitals, focusing on key topical products.」